Galapagos changed course earlier this year, announcing it no longer wanted to focus on cell therapy and would seek buyers for this business. After shopping around the assets for months, Galapagos ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Down syndrome affects around one in 640 children born in the US every year, and is the most common genetic cause of intellectual disability. About 15% of Downs cases are due to the presence of an ...